USDA EXPORT VERIFICATION PROGRAM FOR SUPPLIERS OF SHELL EGGS FOR PROCESSING FOR THE EUROPEAN UNION

1 Purpose

This document provides the specified product requirements for shell eggs intended to be used in FSIS-inspected egg products (i.e. dried, frozen, or liquid eggs) and exported to the European Union (EU) under the USDA Export Verification (EV) Program.

2 Scope

These requirements apply to shell eggs intended to be used in egg products at an egg products facility under FSIS inspection. U.S. Companies/suppliers must meet the specified product requirements for the EU through this EV Program.

Only companies/suppliers with an approved USDA EV Program for Suppliers of Shell Eggs for Processing for the EU may label and sell product as meeting the specified product requirements for the EU under this program.

3 References

QAD 1000 Procedure: *Quality Systems Verification Programs, General Policies and Procedures*

USDA FSIS: Export Library – Requirements by Country website

Official Listing of Eligible Suppliers of Eggs for Processing for the EU

4 Mode of Verification

4.1 Verification for this program shall be done semi-annually and offsite via virtual/desk audit.

4.2 When the assigned auditor contacts the company/supplier to schedule this audit, the company/supplier shall set up the virtual meeting via the carrier of their choice (ie. Microsoft Teams, Webex, Zoom, etc.).

4.3 The company/supplier shall provide all records requested by the auditor in support of the specified product requirements listed below. Records may be reviewed by the auditor by sharing desktop/screen or through use of a file sharing system.

5 Specified Product Requirements

5.1 Production records must be maintained for a minimum of three years.

5.2 The company/supplier must provide evidence of regular veterinary visits to the supplier. The frequency of these visits should at minimum be annually.

5.3 Animals must not be administered antimicrobial medicinal products for growth promotion and/or yield increase during their lifetime, including but not limited to bacitracin and bambermycin.

5.4 Animals must not be administered antimicrobials reserved for the treatment of certain infections in humans, as laid down in Commission Implementing Regulation (EU) 2022/1255, during their lifetime. See Appendix 1.

5.5 The company must maintain sufficient records of antimicrobials used, under the discretion of the veterinarian, for purposes other than growth promotion and/or yield increase.

5.6 Identification and segregation of conforming product must be maintained throughout the supply chain. A documented procedure for identification and segregation of conforming product must be maintained.

6 Shipping Documentation

6.1 Identification of conforming product during shipment and delivery must be documented on the shipping documentation (bills of lading, shipping manifests, or letters of guarantee). The shipping documentation must:

6.1.1 Clearly identify the product and product quantity; and

6.1.2 Contain the following applicable statement:

6.1.2.1 “Product Meets EV Program Requirements for EU”

7 Listing of Approved Programs

U.S. companies/suppliers that have demonstrated the ability to produce products in accordance with the EV Program for EU will be listed on the *Official Listing of Eligible Suppliers of Shell Eggs for Processing for the EU.*

8 Responsibilities

U.S. companies/suppliers must meet all policies and procedures outlined in this procedure, and QAD 1000 Procedure: *Quality Systems Verification Programs, General Policies and Procedures.*



Jeff Waite, Branch Chief
Quality Assessment Division
Livestock and Poultry Program

Date Issued 02/11/2026

Appendix 1

Antimicrobials or groups of antimicrobials reserved for treatment of certain infections in humans per Commission Implementing Regulation (EU) 2022/1255 of 19 July 2022

(1) Antibiotics

(a) Carboxypenicillins

(b) Ureidopenicillins

(c) Ceftobiprole

(d) Ceftaroline

(e) Combinations of cephalosporins with beta-lactamase inhibitors

(f) Siderophore cephalosporins

(g) Carbapenems

(h) Penems

(i) Monobactams

(j) Phosphonic acid derivates

(k) Glycopeptides

(l) Lipopeptides

(m) Oxazolidinones

(n) Fidaxomicin

(o) Plazomicin

(p) Glycylcyclines

(q) Eravacycline

(r) Omadacycline

(2) Antivirals

(a) Amantadine

(b) Baloxavir marboxil

(c) Celgosivir

(d) Favipiravir

(e) Galidesivir

(f) Lactimidomycin

(g) Laninamivir

(h) Methisazone/metisazone

(i) Molnupiravir

(j) Nitazoxanide

(k) Oseltamivir

(l) Peramivir

(m) Ribavirin

(n) Rimantadine

(o) Tizoxanide

(p) Triazavirin

(q) Umifenovir

(r) Zanamivir

(3) Antiprotozoals

(a) Nitazoxanide